DA 1726
Code DA-1726
MetaVia's weekly oxyntomodulin analog acts on GLP-1 and glucagon receptors. An interim Phase 1 Part 3B analysis showed 13.5% placebo-adjusted weight loss and a 68% placebo-adjusted cut in liver fat at Day 109, by the company's account.
DA-1726 comes from MetaVia and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Obesity and cardiometabolic disease; Phase 2 planned in MetALD and alcohol-associated liver disease. It stands at Phase 1 on the board, with 1 news move logged; the latest is dated 10 Nov 2026.
- 05ApprovedCleared for sale in at least one major market for this use.
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1Here now
- Company
- MetaViawith Dong-A ST (license agreement)
- Mechanism
- Oxyntomodulin analog; GLP-1 and glucagon receptor dual agonist with a 3:1 GLP1R to GCGR potency ratio
- Given as
- weekly injection
- Lead use on the board
- Obesity and cardiometabolic disease; Phase 2 planned in MetALD and alcohol-associated liver disease
- Moves logged
- 1latest today
DA 1726 news moves
-
MetaVia ObesityWeek poster on DA 1726 arrives with its data still unseen
MetaVia will present a poster on DA-1726, its weekly GLP-1 and glucagon dual agonist, at ObesityWeek 2026 in Washington DC. The release names no new data, so the molecule joins our board at Phase 1 with a flat signal.
Other incretins molecules on the board, with their current stage.